Developer docs
API playgroundTry for free, no card

Search company profiles

Flexipharm Austrading

Full company profile

uuid0022moy

Namestring
Flexipharm Austrading
Legal namestring
Flexipharm Austrading Limited
Company typeenum
Private
Founded yearint
2018
Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersMarkyate, United Kingdom
HQ citystring
Markyate
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, injectable medicines, critical care drugs, hospital pharmaceuticals, generic injectables
Industry1 code
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Medical Equipment and Supplies Manufacturing3391
SIC code1 code
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Specialty Pharmaceuticals (Injectable Critical Care Medicines)
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical product sales to NHS hospitals
TypeOne Time License
Description

Flexipharm acquires exclusive distribution rights to novel or better presentations of injectable critical care medicines and supplies them to UK NHS and independent hospitals. The company generates revenue through product sales at prices lower than existing alternatives, targeting minimum 7.5% cost savings versus competitor products. They submit products for inclusion on NHS Framework Agreements for transparent pricing.

flexipharmaustrading.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure
Pricing details2 tiers
1Methylthioninium Chloride 10mg/ml vials - £150.00 per pack
ModelUnit PricingBilling cadencePay-as-you-go
Notes

NHS/List price is £150.00 per pack, which is 23% cheaper than the alternative ampoule product at £196.89 per pack (price difference of £46.89).

flexipharmaustrading.com
2Target pricing for all products - minimum 7.5% cost saving
ModelUnit PricingBilling cadencePay-as-you-go
Notes

All products target a minimum of 7.5% cost saving versus the current or equivalent product. Products included on NHS Framework Agreements for transparent pricing.

flexipharmaustrading.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Flexipharm Austrading is a UK specialty pharmaceutical company that acquires exclusive distribution rights to novel or better presentations of injectable critical care medicines and supplies them to UK NHS and independent hospitals. Its portfolio comprises four injectable critical care medicines (Arsenic Trioxide Phebra, Methylthioninium Chloride, Metaraminol 10mg/ml and Metaraminol 0.5mg/ml) presented in vials rather than ampoules to reduce sharps injuries and consumable costs. Products are manufactured by Australian partner Phebra at an MHRA, EMA and FDA approved facility and distributed via exclusive wholesaler Mawdsleys.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 23% cost savings on Methylthioninium Chloride (£150 vs £196.89 for ampoule alternative)
+2 more records
Product overview1 text field

Flexipharm Austrading is a specialty pharmaceutical company that supplies generic injectable critical care medicines to UK NHS and independent hospitals. The company focuses on supplying vials (rather than traditional ampoules) of established 'gold standard' medicines that offer improvements in safety, cost, and administration. The product portfolio includes four injectable medicines: Arsenic Trioxide Phebra (for acute promyelocytic leukaemia), Methylthioninium Chloride (for methaemoglobinaemia), and two Metaraminol presentations (10mg/ml and 0.5mg/ml for acute hypotension). All products are supplied in vial format to reduce sharps injuries and eliminate the need for filter straws/needles. The company operates under exclusive distribution agreements with Australian manufacturer Phebra Pty Ltd.

Product and service4 records
1Arsenic Trioxide Phebra 1mg/ml Concentrate for Solution for Infusion
CategorySpecialty Pharmaceuticals — Injectable Critical Care Medicine
Description

Novel vial presentation of arsenic trioxide concentrate for solution for infusion, indicated for the treatment of low-intermediate risk Acute Promyelocytic Leukaemia (APML). Available in 10ml and 20ml vials, supplied in Type I moulded glass with a protective plastic shrink-wrap sleeve and base cup. Eliminates the need for filter needles or straws and reduces sharps injury risk for NHS specialist pharmacists.

2Methylthioninium Chloride 10mg/ml Sterile Concentrate for Solution for Injection
CategorySpecialty Pharmaceuticals — Injectable Critical Care Medicine
Description

First and only generic licensed vial presentation of methylthioninium chloride, indicated for treatment of medicinal, chemical-induced and genetic methaemoglobinaemia. Priced at £150 per pack, 23% cheaper than the alternative ampoule product at £196.89, with an improved in-use shelf life of up to 24 hours from opening.

3Metaraminol 10mg/ml Solution for Injection/Infusion
CategorySpecialty Pharmaceuticals — Injectable Critical Care Medicine
Description

First user-safety focused vial presentation of Metaraminol 10mg/ml in the UK, indicated for treatment of acute hypotension due to loss of vasoconstrictor tone as may occur during spinal anaesthesia. Typically used to prepare an infusion.

4Metaraminol 0.5mg/ml (5mg in 10ml) Solution for Injection/Infusion
CategorySpecialty Pharmaceuticals — Injectable Critical Care Medicine
Description

First vial presentation of Metaraminol 0.5mg/ml (5mg in 10ml) available in the UK, indicated for treatment of acute hypotension due to loss of vasoconstrictor tone as may occur during spinal anaesthesia. This strength is typically administered as a bolus in the operating theatre.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-01-01
Description

Exclusive license and distribution agreement with Phebra Pty Ltd, an Australian company that develops, manufactures and supplies high quality and innovative pharmaceuticals for the hospital specialty pharmaceutical market. Phebra has a modern specialist injectable medicines facility approved by MHRA, EMA, and FDA. This partnership has enabled launch of multiple injectable critical care medicines since 2019 including Arsenic Trioxide Phebra (approved May 2019), Methylthioninium Chloride, and Metaraminol products.

2Mawdsleys
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2019-01-01
Description

Exclusive wholesaler partnership with Mawdsleys for distribution of all products to NHS and independent hospitals. Products including Arsenic Trioxide Phebra and Methylthioninium Chloride are available from Mawdsleys.

flexipharmaustrading.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Australian specialty injectable pharmaceutical manufacturer and Flexipharm's exclusive partner and equity holder. While not a direct competitor, Phebra is the upstream manufacturing partner whose portfolio drives Flexipharm's product roadmap — a critical ecosystem participant.

TypeBroad incumbent
Description

Global specialty pharmaceutical company with a substantial hospital injectables franchise serving the UK NHS. Comparable in product category (sterile injectable generics) and customer base (UK hospitals), but at much larger scale and with broader geographic reach.

TypeDirect peer
Description

UK specialty pharmaceutical company focused on hospital injectable medicines, including critical care products. Comparable to Flexipharm in target market (UK hospitals), product category (injectables), and specialty-pharma distribution model.

TypeDirect peer
Description

European specialty manufacturer of hospital injectable generics. Comparable to Flexipharm in focus on injectable hospital generics, supply to UK/NHS, and product format including ampoules and vials.

TypeBroad incumbent
Description

Global specialty pharmaceutical company with a meaningful hospital injectables portfolio in the UK and Europe. Comparable in therapeutic focus (specialty/hospital injectables) and customer base, but operates as a much larger incumbent across multiple geographies.

TypeEmerging player
Description

European specialty pharmaceutical company focused on niche injectable medicines for hospitals. Comparable in focus on specialty injectable generics for hospital use, though smaller and more regionally concentrated than Flexipharm's current UK footprint.

TypeDirect peer
Description

UK-based specialty pharmaceutical company focused on niche hospital and specialty medicines, often via licensing/distribution arrangements. Closely comparable to Flexipharm in business model (exclusive distribution of partner-manufactured products to UK hospitals), therapeutic focus on hospital injectables, and customer base (NHS).

TypeOthers
Description

UK pharmaceutical wholesaler and Flexipharm's exclusive distribution partner. As Flexipharm's wholesaler of record, Mawdsleys is a channel partner rather than competitor, but shares the same NHS-facing specialty pharma distribution ecosystem.

TypeDirect peer
Description

European specialty pharmaceutical company with significant hospital injectables portfolio, including critical care products. Comparable in business model (specialty injectable distribution to hospitals), therapeutic areas (critical care), and product-format focus.

TypeBroad incumbent
Description

UK-headquartered specialty pharmaceutical company with a significant portfolio of established branded and generic medicines, many for hospital use. Comparable in customer base (NHS hospitals) and specialty-pharma positioning, though much larger and broader in scope.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Flexipharm Austrading

Specialty Pharmaceuticals (Injectable Critical Care Medicines)flexipharmaustrading.com

Flexipharm Austrading firmographics

Firmographics
Name
Flexipharm Austrading
Legal name
Flexipharm Austrading Limited
Website
https://flexipharmaustrading.com
Company type
Private
Founded year
2018
Operating status
Operating
Ownership category
akta.pro rank

Flexipharm Austrading industry classification

Industry
Product category
Specialty Pharmaceuticals (Injectable Critical Care Medicines)
NAICS
Medical Equipment and Supplies Manufacturing (3391)
SIC
Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAAAB
Specialty Care Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Specialty pharmaceuticals
  • Injectable medicines
  • Critical care drugs
  • Hospital pharmaceuticals
  • Generic injectables

Where Flexipharm Austrading is headquartered

Location

Headquarters

HQ city
Markyate
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Flexipharm Austrading business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Pharmaceutical product sales to NHS hospitals: Flexipharm acquires exclusive distribution rights to novel or better presentations of injectable critical care medicines and supplies them to UK NHS and independent hospitals. The company generates revenue through product sales at prices lower than existing alternatives, targeting minimum 7.5% cost savings versus competitor products. They submit products for inclusion on NHS Framework Agreements for transparent pricing.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goMethylthioninium Chloride 10mg/ml vials - £150.00 per pack
Unit PricingPay-as-you-goTarget pricing for all products - minimum 7.5% cost saving

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Flexipharm Austrading product offering

Product offering

Core offering

Flexipharm Austrading is a UK specialty pharmaceutical company that acquires exclusive distribution rights to novel or better presentations of injectable critical care medicines and supplies them to UK NHS and independent hospitals. Its portfolio comprises four injectable critical care medicines (Arsenic Trioxide Phebra, Methylthioninium Chloride, Metaraminol 10mg/ml and Metaraminol 0.5mg/ml) presented in vials rather than ampoules to reduce sharps injuries and consumable costs. Products are manufactured by Australian partner Phebra at an MHRA, EMA and FDA approved facility and distributed via exclusive wholesaler Mawdsleys.

Product overview

Flexipharm Austrading is a specialty pharmaceutical company that supplies generic injectable critical care medicines to UK NHS and independent hospitals. The company focuses on supplying vials (rather than traditional ampoules) of established 'gold standard' medicines that offer improvements in safety, cost, and administration. The product portfolio includes four injectable medicines: Arsenic Trioxide Phebra (for acute promyelocytic leukaemia), Methylthioninium Chloride (for methaemoglobinaemia), and two Metaraminol presentations (10mg/ml and 0.5mg/ml for acute hypotension). All products are supplied in vial format to reduce sharps injuries and eliminate the need for filter straws/needles. The company operates under exclusive distribution agreements with Australian manufacturer Phebra Pty Ltd.

Differentiator

Problem solved

Functional benefit

Products and services

  • Arsenic Trioxide Phebra 1mg/ml Concentrate for Solution for Infusion Novel vial presentation of arsenic trioxide concentrate for solution for infusion, indicated for the treatment of low-intermediate risk Acute Promyelocytic Leukaemia (APML). Available in 10ml and 20ml vials, supplied in Type I moulded glass with a protective plastic shrink-wrap sleeve and base cup. Eliminates the need for filter needles or straws and reduces sharps injury risk for NHS specialist pharmacists.
  • Methylthioninium Chloride 10mg/ml Sterile Concentrate for Solution for Injection First and only generic licensed vial presentation of methylthioninium chloride, indicated for treatment of medicinal, chemical-induced and genetic methaemoglobinaemia. Priced at £150 per pack, 23% cheaper than the alternative ampoule product at £196.89, with an improved in-use shelf life of up to 24 hours from opening.
  • Metaraminol 10mg/ml Solution for Injection/Infusion First user-safety focused vial presentation of Metaraminol 10mg/ml in the UK, indicated for treatment of acute hypotension due to loss of vasoconstrictor tone as may occur during spinal anaesthesia. Typically used to prepare an infusion.
  • Metaraminol 0.5mg/ml (5mg in 10ml) Solution for Injection/Infusion First vial presentation of Metaraminol 0.5mg/ml (5mg in 10ml) available in the UK, indicated for treatment of acute hypotension due to loss of vasoconstrictor tone as may occur during spinal anaesthesia. This strength is typically administered as a bolus in the operating theatre.

Quantifiable outcome

  • 23% cost savings on Methylthioninium Chloride (£150 vs £196.89 for ampoule alternative)
  • +2 more outcomes

Companies that use Flexipharm Austrading

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Flexipharm Austrading technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Flexipharm Austrading partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Phebra Pty LtdcoreStrategic or Co-development Partner · 1 January 2019Exclusive license and distribution agreement with Phebra Pty Ltd, an Australian company that develops, manufactures and supplies high quality and innovative pharmaceuticals for the hospital specialty pharmaceutical market. Phebra has a modern specialist injectable medicines facility approved by MHRA, EMA, and FDA. This partnership has enabled launch of multiple injectable critical care medicines since 2019 including Arsenic Trioxide Phebra (approved May 2019), Methylthioninium Chloride, and Metaraminol products.
  • MawdsleyscoreChannel Partner/ Reseller/ Distributor · 1 January 2019Exclusive wholesaler partnership with Mawdsleys for distribution of all products to NHS and independent hospitals. Products including Arsenic Trioxide Phebra and Methylthioninium Chloride are available from Mawdsleys.

Scale indicators8 records

Recent moves6 records

Expansion highlights4 records

Flexipharm Austrading competitors and assessment

Company assessment

Others

  • Phebra Pty Ltd: Australian specialty injectable pharmaceutical manufacturer and Flexipharm's exclusive partner and equity holder. While not a direct competitor, Phebra is the upstream manufacturing partner whose portfolio drives Flexipharm's product roadmap — a critical ecosystem participant.
  • Mawdsleys: UK pharmaceutical wholesaler and Flexipharm's exclusive distribution partner. As Flexipharm's wholesaler of record, Mawdsleys is a channel partner rather than competitor, but shares the same NHS-facing specialty pharma distribution ecosystem.

Broad incumbents

  • Hikma Pharmaceuticals: Global specialty pharmaceutical company with a substantial hospital injectables franchise serving the UK NHS. Comparable in product category (sterile injectable generics) and customer base (UK hospitals), but at much larger scale and with broader geographic reach.
  • Aspen Pharmacare: Global specialty pharmaceutical company with a meaningful hospital injectables portfolio in the UK and Europe. Comparable in therapeutic focus (specialty/hospital injectables) and customer base, but operates as a much larger incumbent across multiple geographies.
  • Advanz Pharma (formerly Mercury Pharma): UK-headquartered specialty pharmaceutical company with a significant portfolio of established branded and generic medicines, many for hospital use. Comparable in customer base (NHS hospitals) and specialty-pharma positioning, though much larger and broader in scope.

Direct peers

  • Martindale Pharma: UK specialty pharmaceutical company focused on hospital injectable medicines, including critical care products. Comparable to Flexipharm in target market (UK hospitals), product category (injectables), and specialty-pharma distribution model.
  • Hameln Pharmaceuticals: European specialty manufacturer of hospital injectable generics. Comparable to Flexipharm in focus on injectable hospital generics, supply to UK/NHS, and product format including ampoules and vials.
  • Flynn Pharma: UK-based specialty pharmaceutical company focused on niche hospital and specialty medicines, often via licensing/distribution arrangements. Closely comparable to Flexipharm in business model (exclusive distribution of partner-manufactured products to UK hospitals), therapeutic focus on hospital injectables, and customer base (NHS).
  • Ethypharm: European specialty pharmaceutical company with significant hospital injectables portfolio, including critical care products. Comparable in business model (specialty injectable distribution to hospitals), therapeutic areas (critical care), and product-format focus.

Emerging players

  • Stragen Pharma: European specialty pharmaceutical company focused on niche injectable medicines for hospitals. Comparable in focus on specialty injectable generics for hospital use, though smaller and more regionally concentrated than Flexipharm's current UK footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Flexipharm Austrading compliance and trust

Trust signal

Compliance6 records

Flexipharm Austrading financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Flexipharm Austrading leadership team

Management profile

Number of profiles

Profiles1 record

Flexipharm Austrading funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Flexipharm Austrading M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Flexipharm Austrading

What does Flexipharm Austrading do?

Flexipharm Austrading is a UK specialty pharmaceutical company that acquires exclusive distribution rights to novel or better presentations of injectable critical care medicines and supplies them to UK NHS and independent hospitals. Its portfolio comprises four injectable critical care medicines (Arsenic Trioxide Phebra, Methylthioninium Chloride, Metaraminol 10mg/ml and Metaraminol 0.5mg/ml) presented in vials rather than ampoules to reduce sharps injuries and consumable costs. Products are manufactured by Australian partner Phebra at an MHRA, EMA and FDA approved facility and distributed via exclusive wholesaler Mawdsleys.

Is Flexipharm Austrading a public or private company?

Flexipharm Austrading is a private company. It is classified as corporate owned and is currently operating.

When was Flexipharm Austrading founded?

Flexipharm Austrading was founded in 2018.

Where is Flexipharm Austrading based?

Flexipharm Austrading is headquartered in Markyate, United Kingdom, in the Europe region.

How does Flexipharm Austrading make money?

One revenue line is on record: pharmaceutical product sales to NHS hospitals.

Who are Flexipharm Austrading's main competitors?

Others on record are Phebra Pty Ltd and Mawdsleys. Broad incumbents are Hikma Pharmaceuticals, Aspen Pharmacare and Advanz Pharma (formerly Mercury Pharma). Direct peers are Martindale Pharma, Hameln Pharmaceuticals, Flynn Pharma and Ethypharm. Stragen Pharma is listed as an emerging player.

Does Flexipharm Austrading have an API?

No public API is recorded for Flexipharm Austrading.

What industry is Flexipharm Austrading in?

Flexipharm Austrading's product category is Specialty Pharmaceuticals (Injectable Critical Care Medicines). Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals. Its NAICS code is 3391 and its SIC code is 5122.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswirePhebra Acquires Equity Stake in UK Specialty Hospital Pharma Company Flexipharm AustradingAustralian pharmaceutical group Phebra Holdings has completed a share purchase agreement to acquire an equity stake in UK specialty hospital pharmaceutical company Flexipharm Austrading Limited. This strategic investment deepens the existing collaboration between the two entities, leveraging Flexipharm's infrastructure to advance market access for critical care products in the UK and potentially wider European markets.PR NewswireFlexipharm Austrading Announces Launch of First Vial and First Generic Presentation of Methylthioninium ChlorideFlexipharm Austrading announced the commercial launch in the UK of Methylthioninium Chloride 10mg/ml Sterile concentrate, the first and only generic licensed product available in a preferred vial presentation rather than the traditional ampoule. The product offers the NHS a 23% cost reduction (\u00a346.89 vs \u00a3196.89 per pack), eliminates sharps injury risk for healthcare workers, and provides improved shelf life of up to 24 hours after opening compared to the ampoule product which must be used immediately. The launch validates the company's strategy of providing NHS staff with improved product presentations for established hospital medicines.PR NewswireFlexipharm Austrading Announces Product Update on Arsenic Trioxide PhebraFlexipharm Austrading announced an MHRA-approved update to the storage stability specifications for its arsenic trioxide injection product, Arsenic Trioxide Phebra, extending in-use stability time from 24 to 48 hours at room temperature and from 48 to 72 hours under refrigeration. The vial presentation, the first of its kind for arsenic trioxide in the UK, reduces sharps injury risks compared to traditional glass ampoules and eliminates the need for filter needles or straws during preparation. The product is manufactured by Australian partner Phebra Pty Ltd and distributed exclusively by Flexipharm in the UK.PR NewswireFlexipharm Austrading Announces Launch of Arsenic Trioxide Phebra (Arsenic Trioxide 1mg/ml Concentrate for Solution for Infusion)Flexipharm Austrading announced the commercial launch of Arsenic Trioxide Phebra in the UK following MHRA Marketing Authorisation approval, making it the first generic arsenic trioxide injection product available in the country. The product, supplied by Australian partner Phebra Pty Ltd, uses a safer glass vial presentation that reduces sharps injury risks and is priced 7.7% lower than traditional ampoules at £2,700 per pack of 10 x 10ml vials. The company, founded in 2018, aims to address supply security and presentation concerns for critical hospital medicines used by the NHS.